Investing.comDoubao · 实盘可交易 · 做多市场:美股▲ 赚 +9.57% · 已结算把握 6/10
北京时间·🕒 发布 19:04:38·⟳ 抓取 19:06:09 +1m31s·⚡ 决策 10-19 19:11:05 +4m56s·8.3 天前
Veradermics口服米诺地尔VDPHL01第二个关键III期Study 304阳性，两项注册研究双双达标为NDA铺路
第二个关键III期阳性且安全性干净，实质性消除注册风险并为NDA铺路，方向明确、标的直接可交易；但市场已提前预期成功（读出日期公开、股价此前大幅上涨、近5日获利回吐-17%），边际惊喜低于首个Study 302，故以小仓、限制追高的条件单参与。
📄 原文Investing.com↗ 原文
Veradermics reports phase 3 trial success for hair loss drug
Oil prices dip as Trump waives Russia sanctions NEW HAVEN, Conn. - Veradermics, Incorporated (NYSE:MANE) announced posi…
▲ 赚 +9.57%入场 10-19 盘前首笔 @109.76 → 离场 10-20 常规开盘 @120.62
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑双III期阳性且无心脏事件，NDA去风险；小仓限价防高开见光
怎么买 限价买入 不高于昨收 +5%、仅下一个交易日，不成交作废
怎么卖 止盈 +12%(半仓)/+22%(清仓) · 止损 -10% · 时间止损 5日
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 MANE.US Veradermics, Incorporated
5 个交易日均已收盘,数据完整 · 美股含盘前盘后(灰底:美东 04:00 至收盘后 4 小时)
- 发布 10-19 19:04 北京(美东 10-19 07:04)
- 抓取 10-19 19:06 北京(美东 10-19 07:06)
- 入场 10-19 19:09 北京(美东 10-19 07:09) · 盘前首笔 @109.76
- 决策 10-19 19:11 北京(美东 10-19 07:11)
- 离场 10-20 21:30 北京(美东 10-20 09:30) · 常规开盘 @120.62
时间轴只含交易时段(午休、隔夜已压缩);横轴为北京时间,悬停看当地时间;蓝虚线 = 纸面入场价;建仓日图红线在昨收上方、绿线在下方
成交明细 · 纸面
做多 MANE.US Veradermics, Incorporated
| 收益状态 | +9.57% 已平仓 |
|---|---|
| 进场成交 | 2026-10-19 · 盘前首笔 · 10-19 19:09 北京 · @109.759 · 成交 7% |
| 离场成交 | 2026-10-20 · 常规开盘 · @120.62 |
| 毛收益 | +9.89% |
| 成本 | +0.32% |
| 净收益 | +9.57% |
| 计入收益 | +0.63% |
| 建仓日 | 2026-10-19 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-28 02:20
研究档案
结论摘要
VDPHL01两项关键III期均阳性、无心脏安全事件，上市路径基本打通，潜在成为首个口服非激素脱发药；但这是被市场等待的确认性读出、预期已部分定价，盘前流动性极薄且信号混乱，故小仓限价参与、严格止损。
消息传播链
- 公司发布新闻稿并安排电话会讨论Study 304顶线结果，时间为美东10月19日早晨（美股盘前）市场反应:盘前价格在100.06-120.7美元间剧烈波动，最新约107美元、成交量仅约3500股，流动性极薄
- Investing.com转发完整疗效与安全性数据，AI生成、编辑审核
关键理由
- 双注册研究（302+304，>1000人）全部p<0.0001且无心脏相关AES，FDA申报所需疗效与安全性证据基本齐备，关键研发风险消除
- 近5日股价回调约17%、读出前获利了结，若数据获机构认可存在预期差修复空间，直接受益标的唯一
主要风险
- 这是公开日程的第二个确认性试验，市场已计入成功，边际惊喜远小于4月首个Study 302（当时+47%），存在sell-the-news高开低走风险
- 盘前价格在100-120美元间剧烈摆动、成交量仅数千股，开盘可能大幅跳空；FDA后续若要求额外安全性试验或女性Study 306失败将重估
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-18 · 影响 weakens
未发现新的安全性或监管利空；本研究明确无治疗相关SAE及心脏相关AES。主要反方是估值已高、市场提前定价成功（AInvest标题）
检索:Veradermics MANE 安全性 心脏 下调 估值 风险 2026年10月 原文 ↗ - 做多前查反向 · 来源 futu行情 · 日期 2026-10-16 · 影响 weakens
近5日-16.9%、距60日高点-20%，读出前明显获利回吐，既释放部分估值压力也反映分歧；20日波动率约5%/日，单股波动极高
检索:Veradermics 近期股价 获利回吐 高位 回调
先例如何影响了这次决策
对本次决策的影响:确认做多方向与高波动属性，但因边际惊喜递减和price-in高企，仓位降至small、设置5%追高上限和较紧止损
方向:唯一高相似对齐先例显示阳性pivotal读出后方向强烈向上、1-5日全胜（+48%~+57%）
涨幅量级:首个pivotal单日+47.6%但置信区间极宽（n=1）；本次为已被预期的第二个确认性试验，不能照搬该幅度，止盈取显著保守的12%/22%
形态:先例首日高开后盘中宽幅震荡（开81、高101.8、低73.4、收100.1），次日继续走高；提示阳性数据有承接但波动极大，需限制追高
历史先例(按相似度)
- 相似度 9/10 MANE 2026-04-27 Study 302阳性topline，盘前IR发稿，股价此前低位、市场担忧口服米诺地尔心脏安全性 原文 ↗
事件后 +1日 +47.5% · +2日 +52.0% · +3日 +57.1% · +4日 +45.9% · +5日 +48.9%
⚠未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同公司同药物同适应症的首个关键性阳性读出，唯一差异是本次为第二个确认性试验、成功预期更高
经验:干净的阳性pivotal可带来约48%单日重定价，但那是首个去风险事件；确认性试验的边际反应通常显著更小
工具执行结果 · 成功 7 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`mane veradermics 三期临床 米诺地尔 脱发 成功 | veradermics study 302 306 minoxidil topline | veradermics vdphl01 phase 3 study 304 oral minoxidil hair loss positive results`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 412 ms
{ - web_search 成功 doubao_search · 1,520 ms
豆包搜索结果（原始查询:Veradermics VDPHL01 Study 304 Phase 3 positive results oral minoxidil press release；API SearchType:web） - web_search 成功 doubao_search · 1,529 ms
豆包搜索结果（原始查询:Veradermics MANE stock Study 304 readout reaction analyst；API SearchType:web） - web_search 成功 doubao_search · 1,609 ms
豆包搜索结果（原始查询:ir.veradermics.com Study 304 positive topline October 2026 news release；API SearchType:web） - event_study 成功 stock_tools HTTP · 16 ms
{
原文全文
展开原文 · 2,021 字
Oil prices dip as Trump waives Russia sanctions
NEW HAVEN, Conn. - Veradermics, Incorporated (NYSE:MANE) announced positive results from its Phase 3 clinical trial evaluating VDPHL01, an oral extended-release minoxidil formulation for male pattern hair loss, according to a press release statement.
Study 304 enrolled 536 participants randomized to receive VDPHL01 8.5mg once daily, VDPHL01 8.5mg twice daily, or placebo. The trial met all primary and secondary endpoints at Month 6.
Participants receiving once-daily dosing showed an average increase of 28.6 hairs/cm² while twice-daily dosing resulted in 36.4 hairs/cm², compared to 6.6 hairs/cm² for placebo. Both treatment arms achieved statistical significance with p<0.0001.
For patient-reported outcomes, 55.7% of once-daily participants and 68.7% of twice-daily participants reported "improved" or "much improved" hair coverage on the Androgenetic Alopecia Impact Rating Scale, compared to 15.0% of placebo participants.
The most common treatment-emergent adverse events were peripheral edema, occurring in 2.8% of once-daily and 4.5% of twice-daily participants versus 0.6% for placebo, and hypertrichosis, occurring in 2.2% of once-daily and 9.0% of twice-daily participants. No treatment-related serious adverse events or cardiac-related adverse events of special interest were observed.
The company previously reported positive results from Study 302 in April 2026, which enrolled over 500 male participants. Combined, the two registration-directed studies include data from more than 1,000 participants.
Veradermics anticipates reporting 12-month data from Study 302 later this year. The company completed enrollment for Study 306, evaluating VDPHL01 in female pattern hair loss, in August, with topline data expected in the first half of 2027.
VDPHL01 would be the first FDA-approved oral non-hormonal treatment for pattern hair loss if approved.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW HAVEN, Conn. - Veradermics, Incorporated (NYSE:MANE) announced positive results from its Phase 3 clinical trial evaluating VDPHL01, an oral extended-release minoxidil formulation for male pattern hair loss, according to a press release statement.
Study 304 enrolled 536 participants randomized to receive VDPHL01 8.5mg once daily, VDPHL01 8.5mg twice daily, or placebo. The trial met all primary and secondary endpoints at Month 6.
Participants receiving once-daily dosing showed an average increase of 28.6 hairs/cm² while twice-daily dosing resulted in 36.4 hairs/cm², compared to 6.6 hairs/cm² for placebo. Both treatment arms achieved statistical significance with p<0.0001.
For patient-reported outcomes, 55.7% of once-daily participants and 68.7% of twice-daily participants reported "improved" or "much improved" hair coverage on the Androgenetic Alopecia Impact Rating Scale, compared to 15.0% of placebo participants.
The most common treatment-emergent adverse events were peripheral edema, occurring in 2.8% of once-daily and 4.5% of twice-daily participants versus 0.6% for placebo, and hypertrichosis, occurring in 2.2% of once-daily and 9.0% of twice-daily participants. No treatment-related serious adverse events or cardiac-related adverse events of special interest were observed.
The company previously reported positive results from Study 302 in April 2026, which enrolled over 500 male participants. Combined, the two registration-directed studies include data from more than 1,000 participants.
Veradermics anticipates reporting 12-month data from Study 302 later this year. The company completed enrollment for Study 306, evaluating VDPHL01 in female pattern hair loss, in August, with topline data expected in the first half of 2027.
VDPHL01 would be the first FDA-approved oral non-hormonal treatment for pattern hair loss if approved.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
3d142d4e2b· 2026-10-19 19:11 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前